# EDGAR Filing Document

**Accession Number:** 0001415397
**File Stem:** 0001213900-23-023667
**Filing Date:** 2023-3
**Character Count:** 4178
**Document Hash:** ff85ffa11f32f4e6ec0f4f9911d298e3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-023667.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001213900-23-023667

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230327

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230328

**DATE AS OF CHANGE**: 20230328

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Raphael Pharmaceutical Inc.
- **CENTRAL INDEX KEY:** 0001415397
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **IRS NUMBER:** 260204284
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-53002
- **FILM NUMBER:** 23769401

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 105 - 5348 VEGAS DR.
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89108
- **BUSINESS PHONE:** 702-442-1166

**MAIL ADDRESS:**
- **STREET 1:** SUITE 105 - 5348 VEGAS DR.
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Easy Energy Inc
- **DATE OF NAME CHANGE:** 20071017

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **March 27, 2023**

**RAPHAEL PHARMACEUTICAL INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-53002** | **26-0204284** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **4 Lui Paster**<br> **Tel Aviv-Jaffa, Israel**  | **6803605** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**+972 74 710 7171**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| N/A | N/A | N/A |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01. Other Events**

On March 27, 2023, the Israeli Ministry of Health approved Raphael Pharmaceutical Inc.'s application to commence a Phase IIa clinical trial in COVID-19 patients under the protocol that was approved by the Helsinki Committee at Rambam Hospital on December 8, 2022. The clinical trial will involve a cannabis-based drug aimed at mitigating deterioration in COVID-19 patients.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **RAPHAEL PHARMACEUTICAL INC.** | **RAPHAEL PHARMACEUTICAL INC.** |
| By: | /s/ Shlomo Pilo |
| Name: | Shlomo Pilo |
| Title: | Chief Executive Officer |

---

Date: March 28, 2023